1-4 of 4
Madeline Phillips
Close
Sort by
Journal Articles

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Henry Siu Him Chan, MBChB, Madeline Phillips, Sophia Farooki, MD FRCPC, Giovanni Piza Rodriguez, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Vishal Kukreti, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Donna Reece, MD
Journal: Blood
Blood (2016) 128 (22): 3457.
https://doi.org/10.1182/blood.V128.22.3457.3457
Published: 2016
Journal Articles

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

Julie Cote, MD, Madeline Phillips, Eshetu G Atenafu, MSc, PStat, Esther Masih-Khan, PhD, Donna Reece, MD, Christine Chen, MD, Anca Prica, MD, Rodger Tiedemann, MD PhD, Suzanne Trudel, MD, Vishal Kukreti, MD
Journal: Blood
Blood (2016) 128 (22): 2137.
https://doi.org/10.1182/blood.V128.22.2137.2137
Published: 2016
Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis

Donna E. Reece, MD, Madeline Phillips, BAS, Beryl Chung, Christine I. Chen, MD, Esther Masih-Khan, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Suzanne Trudel, MD, Victor H Jimenez-Zepeda, MD, PD, Vishal Kukreti, MD, FRCPC
Journal: Blood
Blood (2013) 122 (21): 3231.
https://doi.org/10.1182/blood.V122.21.3231.3231
Published: 2013
Journal Articles

Induction Therapy With Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) For Primary Plasma Cell Leukemia (pPCL)

Donna E. Reece, MD, Madeline Phillips, BAS, Christine I. Chen, MD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Suzanne Trudel, MD, Esther Masih-Khan, PhD, Victor H Jimenez-Zepeda, MD, PD, Vishal Kukreti, MD, FRCPC
Journal: Blood
Blood (2013) 122 (21): 5378.
https://doi.org/10.1182/blood.V122.21.5378.5378
Published: 2013